ClinicalTrials.Veeva

Menu

Infections With Enterobacteria Producing Carbapenemases at the University Hospitals of Strasbourg (CARBA)

U

University Hospital, Strasbourg, France

Status

Unknown

Conditions

Nfections, Enterobacterial

Study type

Observational

Funder types

Other

Identifiers

NCT04995965
8297 (Other Identifier)

Details and patient eligibility

About

Infections with enterobacteria producing carbapenemases at the University Hospitals of Strasbourg - descriptive epidemiology and risk factors for infection in the event of colonization

There is a worrying situation of an increase in the number of patients colonized with carbapenemase-producing Enterobacteriaceae (CPE) at HUS.

7 to 15% of patients colonized with EPC would develop an infection with EPC. The cohorts published mainly concern patients hospitalized in intensive care. The associated mortality reported in the literature is high (> 25%) and greater than that associated with infection with the same bacterium sensitive to carbapenems.

Enrollment

274 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Major subject (≥18 years old)
  • Subject hospitalized at HUS between 01/01/2011 and 07/31/2021
  • Clinical sample or rectal screening smear finding an enterobacterium producing a carbapenemase (EPC)
  • Subject not having expressed their opposition to participating in the study

Exclusion criteria

  • Subject having expressed opposition to participating in the study
  • Subject under guardianship or guardianship
  • Subject under safeguard of justice

Trial contacts and locations

1

Loading...

Central trial contact

Yves HANSMANN, MD, PhD; Saïd CHAYER, PhD, HDR

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems